# Lexicon Pharmaceuticals, Inc. (LXRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $690M  
**Price:** $1.90 (+1.06%)

> Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases, particularly in cardiometabolic and neurological areas. It offers Sotagliflozin, marketed as Inpefa and Zynquista, an oral dual SGLT1/2 inhibitor that reduces the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The company advances key drug candidates including pilavapadin (LX9211) for diabetic peripheral neuropathic pain, with Phase 3 development cleared by the U.S. FDA following positive Phase 2b results, and LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders exclusively licensed to Novo Nordisk. Additional pipeline efforts target hypertrophic cardiomyopathy with sotagliflozin in the ongoing SONATA-HCM Phase 3 study. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals leverages its genomics platform to identify novel small-molecule therapies addressing unmet needs in chronic pain and cardiometabolic conditions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $50M | $50M | -$49M | -$50M | — |
| 2024 | $6M | $5M | -$197M | -$200M | — |
| 2023 | $1M | $1M | -$172M | -$177M | — |
| 2022 | — | — | -$101M | -$102M | — |
| 2021 | — | — | -$87M | -$88M | — |
| 2020 | $23M | $21M | -$48M | -$59M | — |
| 2019 | $32M | $29M | $141M | $130M | — |
| 2018 | $27M | $24M | -$103M | -$121M | — |
| 2017 | $16M | $14M | -$131M | -$123M | — |
| 2016 | — | — | -$127M | -$131M | — |
| 2015 | $130M | $130M | $1M | -$5M | — |
| 2014 | $23M | — | -$100M | -$100M | — |
| 2013 | $2M | — | -$102M | -$104M | — |
| 2012 | $1M | — | -$108M | -$110M | — |
| 2011 | $2M | — | -$114M | -$116M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $185M | $77M | $108M | $34M | $49M |
| 2024 | $298M | $152M | $146M | $67M | $100M |
| 2023 | $229M | $136M | $93M | $22M | $100M |
| 2022 | $194M | $77M | $117M | $46M | $49M |
| 2021 | $137M | $23M | $114M | $64M | — |
| 2020 | $204M | $47M | $156M | $126M | — |
| 2019 | $418M | $301M | $117M | $36M | $249M |
| 2018 | $284M | $311M | -$26M | $80M | $250M |
| 2017 | $437M | $368M | $68M | $62M | $252M |
| 2016 | $476M | $318M | $168M | $47M | $101M |
| 2015 | $652M | $366M | $286M | $203M | $106M |
| 2014 | $471M | $187M | $284M | $137M | $108M |
| 2013 | $274M | $104M | $170M | $37M | $22M |
| 2012 | $372M | $105M | $267M | $30M | $23M |
| 2011 | $431M | $133M | $298M | $186M | $23M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$68M | — | -$68M |
| 2024 | -$179M | $1M | -$180M |
| 2023 | -$162M | $470,000 | -$162M |
| 2022 | -$89M | $1M | -$90M |
| 2021 | -$87M | $1M | -$88M |
| 2020 | -$143M | $87,000 | -$143M |
| 2019 | $114M | $70,000 | $114M |
| 2018 | -$149M | $95,000 | -$149M |
| 2017 | -$185M | $228,000 | -$186M |
| 2016 | -$176M | $231,000 | -$176M |
| 2015 | $185M | $910,000 | $184M |
| 2014 | -$76M | $80,000 | -$76M |
| 2013 | -$91M | $2M | -$93M |
| 2012 | -$94M | $492,000 | -$95M |
| 2011 | -$88M | $1M | -$89M |

Source: [CompaniesByCap](https://companiesbycap.com/company/LXRX)